Israel’s largest health-care provider on Sunday reported a 94 per cent drop in symptomatic COVID-19 infections among 600,000 people who received two doses of Pfizer’s vaccine in the country’s biggest study to date.
Health maintenance organization (HMO) Clalit, which covers more than half of all Israelis, said the same group was also 92 per cent less likely to develop severe illness from the virus.
The comparison was against a group of the same size, with matching medical histories, who had not received the vaccine.
“It shows unequivocally that Pfizer’s coronavirus vaccine is extremely effective in the real world a week after the second dose, just as it was found to be in the clinical study,” said Ran Balicer, Clalit’s chief innovation officer.
He added that the data indicates the Pfizer vaccine, which was developed in partnership with Germany’s BioNTech, is even more effective two weeks or more after the second shot.
Breaking: analysis of 1.2 million Israelis, half vaccinated by Pfizer, reveals a 94% efficacy in preventing symptomatic disease. 92% drop in severe disease. Analysis done by <a href=”https://twitter.com/RanBalicer?ref_src=twsrc%5Etfw”>@RanBalicer</a> and <a href=”https://twitter.com/ClalitHealth?ref_src=twsrc%5Etfw”>@ClalitHealth</a> . Conducted with individual health data. I expect print to follow.
Researchers at the Weizmann Institute of Science, who have been tabulating national data, said that a sharp decline in hospitalization and serious illness identified earlier among the first age group to be vaccinated — aged 60 or older — was seen for the first time in those aged 55 and older.
Hospitalizations and serious illness were still rising in younger groups who began vaccinations weeks later.
The study has not yet been posted on a pre-print server or reviewed by independent experts.
Israel has been conducting a rapid vaccine rollout and its database offers insights into vaccine effectiveness.
WATCH | Bumps and successes in Israel’s COVID-19 vaccine rollout: